Grant of Interim Extension of the Term of U.S. Patent No. 4,650,787; Sanvar®, 18352 [E9-9145]
Download as PDF
<![CDATA[
18352
Federal Register / Vol. 74, No. 76 / Wednesday, April 22, 2009 / Notices
candidate may not be a registered
foreign agent under the Foreign Agents
Registration Act of 1938, as amended.
Evaluation of applications for
membership in the U.S. Section by
eligible individuals will be based on the
following criteria:
dwashington3 on PROD1PC60 with NOTICES
—A demonstrated commitment by the
individual’s company to the Brazilian
market either through exports or
investment.
—A demonstrated strong interest in
Brazil and its economic development.
—The ability to offer a broad
perspective and business experience
to the discussions.
—The ability to address cross-cutting
issues that affect the entire business
community.
—The ability to initiate and be
responsible for activities in which the
Forum will be active.
Members will be selected on the basis
of who will best carry out the objectives
of the Forum as stated in the Terms of
Reference establishing the U.S.-Brazil
CEO Forum. The U.S. Section of the
Forum should also include members
that represent a diversity of business
sectors and geographic locations. To the
extent possible, Section members also
should represent a cross-section of
small, medium, and large firms.
U.S. members will receive no
compensation for their participation in
Forum related activities. Individual
members will be responsible for all
travel and related expenses associated
with their participation in the Forum,
including attendance at Committee and
Section meetings. Only appointed
members may participate in official
Forum meetings; substitutes and
alternates will not be designated. U.S.
members will normally serve for twoyear terms, but may be reappointed.
To be considered for membership,
please submit the following information
as instructed in the ADDRESSES and
DATES captions above: Name(s) and
title(s) of the individual(s) requesting
consideration; name and address of
company’s headquarters; location for
incorporation; size of the company; size
of company’s export trade, investment,
and nature of operations or interest in
Brazil; and a brief statement of why the
candidate should be considered,
including information about the
candidate’s ability to initiate and be
responsible for activities in which the
Forum will be active. Applications will
be considered as they are received. All
candidates will be notified of whether
they have been selected.
VerDate Nov<24>2008
15:31 Apr 21, 2009
Jkt 217001
Dated: April 15, 2009.
Anne Driscoll,
Director for the Office of South America.
[FR Doc. E9–9292 Filed 4–21–09; 8:45 am]
BILLING CODE P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2009–0016]
Grant of Interim Extension of the Term
of U.S. Patent No. 4,650,787; Sanvar®
AGENCY: United States Patent and
Trademark Office.
ACTION: Notice of interim patent term
extension.
SUMMARY: The United States Patent and
Trademark Office has issued an order
granting interim extension under 35
U.S.C. 156(d)(5) for a fifth one-year
interim extension of the term of U.S.
Patent No. 4,650,787.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to her attention at
(571) 273–7755, or by e-mail to
Mary.Till@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On March 19, 2009, Debiovision Inc.,
the exclusive agent of Debiopharm S.A.
and Debio Recherche Pharmaceutique
S.A., who is the exclusive licensee of
the Administrators of the Tulane
Educational Fund of New Orleans,
Louisiana, the patent owner, timely
filed an application under 35 U.S.C.
156(d)(5) for a fifth interim extension of
the term of U.S. Patent No. 4,650,787.
The patent claims the human drug
product Sanvar® (vapreotide acetate).
The application indicates that a New
Drug Application for the human drug
product Sanvar® (vapreotide acetate)
has been filed and is currently
undergoing regulatory review before the
Food and Drug Administration for
permission to market or use the product
commercially.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00005
Fmt 4703
Sfmt 4703
Review of the application indicates
that except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for an additional one year
as required by 35 U.S.C. 156(d)(5)(B)
and 35 U.S.C. 156(d)(5)(C). Because it is
apparent that the regulatory review
period will continue beyond the
extended expiration date of the patent
(April 25, 2009), a fifth interim
extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
A fifth interim extension under 35
U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,650,787 is granted for a
period of one year from the extended
expiration date of the patent, i.e., until
April 25, 2010.
April 15, 2009.
John J. Doll,
Acting Under Secretary of Commerce for
Intellectual Property and Director of the
United States Patent and Trademark Office.
[FR Doc. E9–9145 Filed 4–21–09; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
National Oceanic and Atmospheric
Administration
RIN 0648–XO70
Incidental Taking of Marine Mammals;
Taking of Marine Mammals Incidental
to the Explosive Removal of Offshore
Structures in the Gulf of Mexico
AGENCY: National Marine Fisheries
Service (NMFS), National Oceanic and
Atmospheric Administration (NOAA),
Commerce.
ACTION: Notice; issuance of letters of
authorization.
SUMMARY: In accordance with the
Marine Mammal Protection Act
(MMPA) and implementing regulations,
notification is hereby given that NMFS
has issued one-year Letters of
Authorization (LOA) to take marine
mammals incidental to the explosive
removal of offshore oil and gas
structures (EROS) in the Gulf of Mexico.
DATES: These authorizations are
effective from May 15, 2009 through
May 14, 2010.
ADDRESSES: The application and LOAs
are available for review by writing to P.
Michael Payne, Chief, Permits,
Conservation, and Education Division,
Office of Protected Resources, National
Marine Fisheries Service, 1315 EastWest Highway, Silver Spring, MD
20910–3235 or by telephoning the
E:\FR\FM\22APN1.SGM
22APN1
]]>Agencies
[Federal Register Volume 74, Number 76 (Wednesday, April 22, 2009)]
[Notices]
[Page 18352]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-9145]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO-P-2009-0016]
Grant of Interim Extension of the Term of U.S. Patent No.
4,650,787; Sanvar[reg]
AGENCY: United States Patent and Trademark Office.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting interim extension under 35 U.S.C. 156(d)(5) for a fifth
one-year interim extension of the term of U.S. Patent No. 4,650,787.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755, or by e-mail to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to a year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On March 19, 2009, Debiovision Inc., the exclusive agent of
Debiopharm S.A. and Debio Recherche Pharmaceutique S.A., who is the
exclusive licensee of the Administrators of the Tulane Educational Fund
of New Orleans, Louisiana, the patent owner, timely filed an
application under 35 U.S.C. 156(d)(5) for a fifth interim extension of
the term of U.S. Patent No. 4,650,787. The patent claims the human drug
product Sanvar[reg] (vapreotide acetate). The application
indicates that a New Drug Application for the human drug product
Sanvar[reg] (vapreotide acetate) has been filed and is
currently undergoing regulatory review before the Food and Drug
Administration for permission to market or use the product
commercially.
Review of the application indicates that except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for an additional one year as
required by 35 U.S.C. 156(d)(5)(B) and 35 U.S.C. 156(d)(5)(C). Because
it is apparent that the regulatory review period will continue beyond
the extended expiration date of the patent (April 25, 2009), a fifth
interim extension of the patent term under 35 U.S.C. 156(d)(5) is
appropriate.
A fifth interim extension under 35 U.S.C. 156(d)(5) of the term of
U.S. Patent No. 4,650,787 is granted for a period of one year from the
extended expiration date of the patent, i.e., until April 25, 2010.
April 15, 2009.
John J. Doll,
Acting Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office.
[FR Doc. E9-9145 Filed 4-21-09; 8:45 am]
BILLING CODE 3510-16-P
